Skip to content
Screener

SELLAS Life Sciences Group, Inc. SLS Q1 2026 earnings

Reported May 12, 2026 · Before market open

EPS-$0.05Beat by $0.01
EPS estimate-$0.06

Next report

Nov 11, 2026 (in 2 months)
EPS estimate-$0.05

Financials

Q1 2026

Income statement

See full
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$759.63M+674%
Enterprise value$653.41M+826%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0×0.0×
Current ratio17.2×+12.6×

FAQ

When did SELLAS Life Sciences Group, Inc. report Q1 2026 earnings?
SELLAS Life Sciences Group, Inc. (SLS) reported Q1 2026 earnings on May 12, 2026 before market open.
What were SELLAS Life Sciences Group, Inc.'s Q1 2026 revenue and EPS?
SELLAS Life Sciences Group, Inc. reported eps of $-0.05 for Q1 2026.
Did SELLAS Life Sciences Group, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.06 by $0.01.
How did SELLAS Life Sciences Group, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 28.6% from $-0.07.
Where can I find SELLAS Life Sciences Group, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001390478-26-000009) and the 10-Q periodic report (0001390478-26-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.